Neuropsychopathology in 7 Patients with the 22q13 Deletion Syndrome: Presence of Bipolar Disorder and Progressive Loss of Skills
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The 22q13 deletion syndrome is characterised by intellectual disability (ID), delayed or absent speech, autistic-like behaviour and minor, nonspecific dysmorphic features. The deletion of the SHANK3 gene is thought to be responsible for these features. In this study, the clinical data of 7 patients with the 22q13 deletion syndrome are presented, obtained by clinical genetic examination, direct behavioural observation and by interview of family members and/or caregivers, complemented by behavioural questionnaires. The specific focus was on behaviour, psychopathology and the level of functioning during life course in order to determine common features that might contribute to the delineation of the syndrome. Major findings were a high incidence of psychiatric disorders, more in particular bipolar disorder (BPD) and attention deficit hyperactivity disorder (ADHD), and a sudden deterioration after acute events, in addition to a progressive loss of skills over years. Therefore, a deletion of SHANK3 may result in a dysfunctional nervous system, more susceptible to developmental problems and psychiatric disorders on the one hand, less able to recuperate after psychiatric and somatic events, and more vulnerable to degeneration at long term on the other hand. These results are exploratory and need to be confirmed in a larger sample.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More gradual regression during development was observed in all these individuals.”
From Brain adaptation and alternative developmental trajectories (2015) · cites this paper as Denayer et al., 2012
In the citing paper
“Some adults with deletions that include the SH3 and multiple ankyrin repeat domains 3 (SHANK3) protein (associated with significant deficits in excitatory synaptic transmission; Shcheglovitov et al., 2013) experience sudden-onset regression in adult life after a significant life event such as a seizure, septic shock, or malignant neuroleptic syndrome (Denayer et al., 2012).”
From Brain adaptation and alternative developmental trajectories (2015) · cites this paper as Denayer et al., 2012
In the citing paper
“SHANK mutations are however not restricted to ASD.”
From Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments (2014) · cites this paper as [45]
In the citing paper
“SHANK3 mutations have been identified in patients suffering from schizophrenia and bipolar disorder [45], [47].”
From Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments (2014) · cites this paper as [45]
In the citing paper
“SHANK3 mutations are highly penetrant (to our knowledge only one validated SHANK3 deletion has been reported to be inherited from a mother with moderate ID [45])”
From Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments (2014) · cites this paper as [45]
Citations
Cites
Einfeld, S. L., & Tonge, B. J. (1995) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02178498 · Cited by 424 · cited 1×
“…Vineland Adaptive Behaviour Scale for individuals with ID (VABS, Vineland-Z) [de Bildt and Kraijer, 2003], the Scale of Pervasive Developmental Disorders in Mentally Retarded Persons (PDD-MRS) [Kraijer and de Bildt, 2005] and the Developmental Behaviour Checklist (DBC) [Einfeld and Tonge, 1995].”
MethodMenten, B., Maas, N., Thienpont, B., Buysse, K., Vandesompele, J., Melotte, C., de Ravel, T., Van Vooren, S., Balikova, I., Backx, L., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.039453 · Cited by 420 · cited 1×
“The genomic DNA of the patients was either screened using the BAC/PAC-array [Menten et al., 2006] or the Oxford Gene Technology (OGT) CytoSure TM ISCA oligoarray set (Oxford Gene Technology, Oxford, UK) containing either 105k or 180k DNA oligonucleotides with a minimum resolution of 200 kb.”
MethodSelf-citationBoeckers, T. M., Bockmann, J., Kreutz, M. R., & Gundelfinger, E. D. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00931.x · Cited by 349
Bonaglia, M. C., Giorda, R., Borgatti, R., Felisari, G., Gagliardi, C., Selicorni, A., & Zuffardi, O. (2001) · The American Journal of Human Genetics · doi:10.1086/321293 · Cited by 309 · cited 2×
“Although deletion sizes differ between patients, the absence of SHANK3 is considered to be responsible for the neurological symptoms of the syndrome [Bonaglia et al., 2001].”
BackgroundMolecular genetics of bipolar disorder and depression
KATO, T. (2007) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2007.01604.x · Cited by 282 · cited 1×
“However, BPD has been associated with several chromosome regions, amongst others 22q13 [Kato, 2007].”
BackgroundPhelan, M. C., Rogers, R. C., Saul, R. A., Stapleton, G. A., Sweet, K., McDermid, H., Shaw, S. R., Claytor, J., Willis, J., & Kelly, D. P. (2001) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20010615)101:2<91::aid-ajmg1340>3.0.co;2-c · Cited by 279 · cited 1×
“The clinical characteristics of this syndrome consist of intellectual disability, delayed or absent speech, autistic-like behaviour and minor, non-specific dysmorphic features [Phelan et al., 2001; Havens et al., 2004; Manning et al., 2004; Cuzmano-Ozog et al., 2007].”
BackgroundBonaglia, M. C., Giorda, R., Beri, S., De Agostini, C., Novara, F., Fichera, M., Grillo, L., Galesi, O., Vetro, A., Ciccone, R., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002173 · Cited by 224 · cited 1×
“A similar severe neurological deterioration was observed in 2 individuals with epilepsy over 40 years in a group of 44 patients with the 22q13 deletion syndrome, and SHANK3 haploinsufficiency was considered as responsible for this [Bonaglia et al., 2011].”
BackgroundManning, M. A., Cassidy, S. B., Clericuzio, C., Cherry, A. M., Schwartz, S., Hudgins, L., Enns, G. M., & Hoyme, H. E. (2004) · Pediatrics · doi:10.1542/peds.114.2.451 · Cited by 172 · cited 1×
“The clinical characteristics of this syndrome consist of intellectual disability, delayed or absent speech, autistic-like behaviour and minor, non-specific dysmorphic features [Phelan et al., 2001; Havens et al., 2004; Manning et al., 2004; Cuzmano-Ozog et al., 2007].”
Backgroundde Bildt, A. A., Kraijer, D. W., Sytema, S., & Minderaa, R. B. (2005) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-004-1033-7 · Cited by 136
Toward an Evidence-Based Assessment of Pediatric Bipolar Disorder
Youngstrom, E. A., Findling, R. L., Kogos Youngstrom, J., & Calabrese, J. R. (2005) · Journal of Clinical Child & Adolescent Psychology · doi:10.1207/s15374424jccp3403_4 · Cited by 110 · cited 1×
“Due to the fact that clinicians are often more familiar with the clinical presentation of the comorbid disorder, like for instance ADHD, some presume that a considerable part of the children diagnosed with ADHD might actually have BPD or an unrecognised comorbid BPD [Youngstrom et al., 2005].”
Background
Cited by
Leblond, C. S., Nava, C., Polge, A., Gauthier, J., Huguet, G., Lumbroso, S., Giuliano, F., Stordeur, C., Depienne, C., Mouzat, K., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004580 · Cited by 630
“This difference in severity of cognitive impairment is in agreement with the observation that SHANK3 mutations are highly penetrant (to our knowledge only one validated SHANK3 deletion has been reported to be inherited from a mother with moderate ID [45]), while for SHANK2, additional genetic/ epigenetic factors might…”
BackgroundResultModeling Autism by SHANK Gene Mutations in Mice
Jiang, Y.-H., & Ehlers, M. D. (2013) · Neuron · doi:10.1016/j.neuron.2013.03.016 · Cited by 488
Soorya, L., Kolevzon, A., Zweifach, J., Lim, T., Dobry, Y., Schwartz, L., Frank, Y., Wang, A. T., Cai, G., Parkhomenko, E., et al. (2013) · Molecular Autism · doi:10.1186/2040-2392-4-18 · Cited by 336
“These cases suggest a common underlying phenotype that includes global developmental delay, severe expressive language delay, hypotonia, autistic features and minor dysmorphic features [21-30].”
BackgroundInfluentialThe emerging role of SHANK genes in neuropsychiatric disorders
Guilmatre, A., Huguet, G., Delorme, R., & Bourgeron, T. (2014) · Developmental Neurobiology · doi:10.1002/dneu.22128 · Cited by 237
“An additional case-report described four patients with PMS and bipolar disorder (Denayer et al., 2012).”
BackgroundBrain adaptation and alternative developmental trajectories
Johnson, M. H., Jones, E. J. H., & Gliga, T. (2015) · Development and Psychopathology · doi:10.1017/s0954579415000073 · Cited by 213
“…3 (SHANK3) protein (associated with significant deficits in excitatory synaptic transmission; Shcheglovitov et al., 2013) experience sudden-onset regression in adult life after a significant life event such as a seizure, septic shock, or malignant neuroleptic syndrome (Denayer et al., 2012).”
De Rubeis, S., Siper, P. M., Durkin, A., Weissman, J., Muratet, F., Halpern, D., Trelles, M. D. P., Frank, Y., Lozano, R., Wang, A. T., et al. (2018) · Molecular Autism · doi:10.1186/s13229-018-0205-9 · Cited by 199
“She had episodic periods of mania and depression, insomnia, decreased appetite and weight loss, unsteady gait, and catatonic posturing, similar to previous reports [51, 55, 56, 59].”
BackgroundResultClinical and genomic evaluation of 201 patients with Phelan–McDermid syndrome
Sarasua, S. M., Boccuto, L., Sharp, J. L., Dwivedi, A., Chen, C.-F., Rollins, J. D., Rogers, R. C., Phelan, K., & DuPont, B. R. (2014) · Human Genetics · doi:10.1007/s00439-014-1423-7 · Cited by 190
Kolevzon, A., Angarita, B., Bush, L., Wang, A. T., Frank, Y., Yang, A., Rapaport, R., Saland, J., Srivastava, S., Farrell, C., et al. (2014) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-6-39 · Cited by 159
“There have been reports of both short stature [27,29-31, 33, 37, 40] and accelerated growth [ 26, 27 , 35, 41 ].”
BackgroundInfluentialA pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome
Kolevzon, A., Bush, L., Wang, A., Halpern, D., Frank, Y., Grodberg, D., Rapaport, R., Tavassoli, T., Chaplin, W., Soorya, L., et al. (2014) · Molecular Autism · doi:10.1186/2040-2392-5-54 · Cited by 140
“Affected individuals also suffer from a heterogeneous array of dysmorphic and medical features, including increased risk of seizures, recurring infections, hypotonia, renal disease, and gastroesophageal reflux [8-17].”
BackgroundPhelan–McDermid Syndrome and SHANK3: Implications for Treatment
Costales, J. L., & Kolevzon, A. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0352-z · Cited by 147
“abnormalities seen on imaging, in addition to hypoplasia of the corpus callosum, ventricular dilatation, and arachnoid cysts [10, 26, 45, 54, 56, 58, 60].”
Serret, S., Thümmler, S., Dor, E., Vesperini, S., Santos, A., & Askenazy-Gittard, F. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0490-1 · Cited by 116
“3 including the SHANK3 gene are responsible of the clinical manifestations of Phelan–McDermid syndrome (PMS) [5].”
BackgroundInfluentialA new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts
Carmassi, C., Del Grande, C., Gesi, C., Musetti, L., & Dell'Osso, L. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s106479 · Cited by 97
Psychiatric illness and regression in individuals with Phelan-McDermid syndrome
Kohlenberg, T. M., Trelles, M. P., McLarney, B., Betancur, C., Thurm, A. E., & Kolevzon, A. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-020-9309-6 · Cited by 98
“Significant cognitive and behavioral regression has been documented in PMS [5, 6, 9, 15, 16, 18, 41].”
BackgroundGuinchat, V., Cravero, C., Diaz, L., Périsse, D., Xavier, J., Amiet, C., Gourfinkel-An, I., Bodeau, N., Wachtel, L., Cohen, D., et al. (2015) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2014.12.020 · Cited by 96
Kolevzon, A., Delaby, E., Berry‐Kravis, E., Buxbaum, J. D., & Betancur, C. (2019) · Molecular Autism · doi:10.1186/s13229-019-0291-3 · Cited by 93
“Proposed diagnosis on review c Unspecified catatonia Bipolar disorder Unspecified mood disorder Metachromatic leukodystrophy Bipolar disorder with catatonia, NF2 Bipolar disorder with unspecified decompensation Loss of skills d + (L, M, A) + (C) + (M, A) Other information Brain CT scan at 14 y and MRI at 30 y both nor…”
InfluentialPhelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment
Harony-Nicolas, H., De Rubeis, S., Kolevzon, A., & Buxbaum, J. D. (2015) · Journal of Child Neurology · doi:10.1177/0883073815600872 · Cited by 81
Soorya, L., Leon, J., Trelles, M. P., & Thurm, A. (2018) · The Clinical Neuropsychologist · doi:10.1080/13854046.2017.1413211 · Cited by 87
Neurobiology of autism gene products: towards pathogenesis and drug targets
Kleijer, K. T. E., Schmeisser, M. J., Krueger, D. D., Boeckers, T. M., Scheiffele, P., Bourgeron, T., Brose, N., & Burbach, J. P. H. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3403-3 · Cited by 75
Holder, J. L., & Quach, M. M. (2016) · Epilepsia · doi:10.1111/epi.13506 · Cited by 86
Deficiency of Shank2 causes mania-like behavior that responds to mood stabilizers
Pappas, A. L., Bey, A. L., Wang, X., Rossi, M., Kim, Y. H., Yan, H., Porkka, F., Duffney, L. J., Phillips, S. M., Cao, X., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92052 · Cited by 67
Identification of 22q13 genes most likely to contribute to Phelan McDermid syndrome
Mitz, A. R., Philyaw, T. J., Boccuto, L., Shcheglovitov, A., Sarasua, S. M., Kaufmann, W. E., & Thurm, A. E. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-017-0042-x · Cited by 79
Choi, S.-Y., Pang, K., Kim, J. Y., Ryu, J. R., Kang, H., Liu, Z., Kim, W.-K., Sun, W., Kim, H., & Han, K. (2015) · Molecular Brain · doi:10.1186/s13041-015-0165-3 · Cited by 69
“Indeed, deletions of SHANK3 gene have been identified in some patients diagnosed with bipolar disorder [51–53].”
BackgroundLevy, T., Foss‐Feig, J. H., Betancur, C., Siper, P. M., Trelles, M. D. P., Halpern, D. B., Frank, Y., Lozano, R., Layton, C., Britvan, B., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab280 · Cited by 75
Zwanenburg, R. J., Ruiter, S., van den Heuvel, E. R., Flapper, B. C. T., & van Ravenswaaij‐Arts, C. M. A. (2016) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-016-9150-0 · Cited by 74
“It has been reported that the loss of skills in PMS is associated with infection, epilepsy, or malignant neuroleptic syndrome [4].”
Variability in Phelan-McDermid Syndrome in a Cohort of 210 Individuals
Nevado, J., García‐Miñáur, S., Palomares‐Bralo, M., Vallespín, E., Guillén‐Navarro, E., Rosell, J., Fenellós, C. B., Mori, M. Á., Milà, M., Campo, M. D., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.652454 · Cited by 62
“Similarly, the risk of psychiatric disorders in PMS increases with age (Denayer et al., 2012; Verhoeven et al., 2012; Kolevzon et al., 2019).”
BackgroundDefinition and clinical variability of SHANK3-related Phelan-McDermid syndrome
Schön, M., Lapunzina, P. D., Nevado, J., Mattina, T., Gunnarsson, C., Hadzsiev, K., Verpelli, C., Bourgeron, T., Jesse, S., van Ravenswaaij‐Arts, C. M. A., et al. (2023) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2023.104754 · Cited by 53
“Used references are: 1: Aldinger et al., 2012; 2: Bonaglia et al., 2011; 3: Brignell et al., 2020; 4: Denayer et al., 2012; 5: De Rubeis et al., 2018; 6: Dhar et al., 2010; 7: Droogmans et al., 2019; 8: Holder and Quach, 2016; 9: Jeffries et al., 2005; 10: Li et al., 2018; 11: Lindquist et al.,…”
BackgroundThurm, A., Powell, E. M., Neul, J. L., Wagner, A., & Zwaigenbaum, L. (2018) · Autism Research · doi:10.1002/aur.1903 · Cited by 44
Childhood disintegrative disorder and autism spectrum disorder: a systematic review
Mehra, C., Sil, A., Hedderly, T. J., Kyriakopoulos, M., Lim, M. J., Turnbull, J., Happe, F. G. E., Baird, G., & Absoud, M. (2018) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14126 · Cited by 47
“This gene has been associated with regression in general, including language, social, and adaptive functions in patients with Phelan–McDermid syndrome, ASD, and bipolar disorder.(46,47) The review data found that both rare genetic variants and copy number variants are implicated in CDD.”
BackgroundEgger, J. I. M., Zwanenburg, R. J., van Ravenswaaij‐Arts, C. M. A., Kleefstra, T., & Verhoeven, W. M. A. (2016) · Genes, Brain and Behavior · doi:10.1111/gbb.12285 · Cited by 45
“…that autistic features have regularly been identified in the PMS phenotype, in postadolescent patients, psychiatric symptoms from the bipolar spectrum appear to be more prominent (Denayer et al. 2012; Pasini et al. 2010; Serret et al. 2015; Verhoeven et al. 2012a,b, 2013; Vucurovic et al. 2012).”
BackgroundInfluentialA longitudinal perspective on the pharmacotherapy of 24 adult patients with Phelan McDermid syndrome
Verhoeven, W. M. A., Egger, J. I. M., & de Leeuw, N. (2019) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2019.103751 · Cited by 45
Egger, J. I. M., Verhoeven, W. M. A., Groenendijk-Reijenga, R., & Kant, S. G. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-220778 · Cited by 44
Characterisation of the clinical phenotype in Phelan-McDermid syndrome
Burdeus-Olavarrieta, M., Cáceres, A. S. J., García-Alcón, A., González‐Peñas, J., Hernández-Jusdado, P., & Parellada, M. (2021) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09370-5 · Cited by 43
“46)), varying autistic symptom severity (median= 6, range=[3-9]), and the lowest proportion of participants with delayed motor milestones.”
BackgroundAltered synaptic ultrastructure in the prefrontal cortex of Shank3-deficient rats
Jacot-Descombes, S., Keshav, N. U., Dickstein, D. L., Wicinski, B., Janssen, W. G. M., Hiester, L. L., Sarfo, E. K., Warda, T., Fam, M. M., Harony-Nicolas, H., et al. (2020) · Molecular Autism · doi:10.1186/s13229-020-00393-8 · Cited by 41
Wan, L., Ai, J.-Q., Yang, C. G., Jiang, J., Zhang, Q., Luo, Z., Huang, R., Tu, T., Pan, A., Tu, E., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.717263 · Cited by 40
The Neurological Manifestations of Phelan-McDermid Syndrome
Frank, Y. (2021) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2021.06.002 · Cited by 40
Kurtas, N. E., Arrigoni, F., Errichiello, E., Zucca, C., Maghini, C., D’Angelo, M. G., Beri, S., Giorda, R., Bertuzzo, S., Delledonne, M., et al. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-105125 · Cited by 39
Deep Phenotyping of Development, Communication and Behaviour in Phelan-McDermid Syndrome
Droogmans, G., Swillen, A., & Buggenhout, G. V. (2019) · Molecular Syndromology · doi:10.1159/000503840 · Cited by 38
“Regression may occur after acute events [Bonaglia et al., 2011; Denayer et al., 2012; Soorya et al., 2013; Serret et al., 2015; Egger et al., 2016].”
BackgroundMethodResultInfluentialSelf-citationMultidisciplinary treatment plan for challenging behaviors in neurodevelopmental disorders
Guinchat, V., Cravero, C., Lefèvre-Utile, J., & Cohen, D. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64148-9.00022-3 · Cited by 37
Baecker, T., Mangus, K., Pfaender, S., Chhabra, R., Boeckers, T. M., & Grabrucker, A. M. (2014) · BioMetals · doi:10.1007/s10534-014-9764-1 · Cited by 36
Etiology of Autism the Complexity of Risk Factors in Autism Spectrum Disorder
Fett‐Conte, A. C., Bossolani-Martins, A. L., & Rosan, D. B. A. (2015) · InTech eBooks · doi:10.5772/59109 · Cited by 29
Subacute Neuropsychiatric Syndrome in Girls WithSHANK3Mutations Responds to Immunomodulation
Bey, A. L., Gorman, M., Gallentine, W. B., Kohlenberg, T. M., Frankovich, J., Jiang, Y., & van Haren, K. P. (2020) · PEDIATRICS · doi:10.1542/peds.2019-1490 · Cited by 29
Rysstad, A. L., Kildahl, A. N., Skavhaug, J. O., Dønnum, M. S., & Helverschou, S. B. (2020) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2020.1756113 · Cited by 25
“…of regression, bipolar disorder, and other psychiatric conditions (Verhoeven et al. 2020, Rowland et al. 2018, Egger et al. 2017, 2016, Serret et al. 2015, Denayer et al. 2012, Verhoeven et al. 2012a, 2012b, Vucurovic et al. 2012) are frequently limited to a primary focus on drug choice and dosage.”
BackgroundResultVitrac, A., Leblond, C. S., Rolland, T., Cliquet, F., Mathieu, A., Maruani, A., Delorme, R., Schön, M., Grabrucker, A. M., van Ravenswaaij‐Arts, C. M. A., et al. (2023) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2023.104732 · Cited by 24
Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders
Samojedny, S., Czechowska, E., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911423 · Cited by 23
“3 deletion, which is associated with a deletion of the SHANK3 gene), four showed the presence of bipolar depression, which suggests a close relationship between Shank3 and this disorder [112].”
BackgroundWade, M., Prime, H., & Madigan, S. L. (2015) · BioMed Research International · doi:10.1155/2015/672784 · Cited by 23
“SHANK3 22q13 Dendrite morphology regulation; synapse scaffolding and plasticity; binding neuroligins [162, 163] [164]”
BackgroundWan, L., Liu, D., Xiao, W., Zhang, B., Yan, X., Luo, Z., & Xiao, B. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01054-x · Cited by 22
Koza, S. A., Tabet, A. C., Bonaglia, M. C., Andres, S., Anderlid, B., Aten, E., Stiefsohn, D., Evans, D. G., van Ravenswaaij‐Arts, C. M. A., & Kant, S. G. (2023) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2023.104773 · Cited by 22
Vogels, A., Droogmans, G., Vergaelen, E., Buggenhout, G. V., & Swillen, A. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000672 · Cited by 21
Self-citationJain, L., Oberman, L. M., Beamer, L., Cascio, L., May, M. M., Srikanth, S., Skinner, C. D., Jones, K. L., Moffitt, B. A., Rogers, C. R., et al. (2021) · Clinical Genetics · doi:10.1111/cge.14074 · Cited by 21
Prospective longitudinal overnight video-EEG evaluation in Phelan–McDermid Syndrome
Khan, O. I., Zhou, X., Leon, J., Kessler, R., Gaughan, T., D’Souza, P., Gropman, A. L., Cohen, N., Rennert, O. M., Buckley, A. W., et al. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.11.034 · Cited by 21
nArgBP2-SAPAP-SHANK, the core postsynaptic triad associated with psychiatric disorders
Lee, S., Kim, J. A., & Chang, S. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-017-0018-5 · Cited by 20
Consensus recommendations on mental health issues in Phelan-McDermid syndrome
van Balkom, I. D. C., Burdeus-Olavarrieta, M., Cooke, J., de Cuba, A. G., Turner, A., Vogels, A., & Maruani, A. (2023) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2023.104770 · Cited by 19
“Symptoms fitting a diagnosis of catatonia have been reported previously, most often in the context of a comorbid psychiatric diagnosis, such as a bipolar disorder (Denayer et al., 2012; Kohlenberg et al., 2020; Kolevzon et al., 2019).”
InfluentialSelf-citationIoannidis, V., Pandey, R., Bauer, H. F., Schön, M., Bockmann, J., Boeckers, T. M., & Lutz, A.-K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02362-y · Cited by 19
Consensus recommendations on communication, language and speech in Phelan-McDermid syndrome
Burdeus-Olavarrieta, M., Nevado, J., van Weering-Scholten, S., Parker, S., & Swillen, A. (2023) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2023.104745 · Cited by 19
Self-citationMatulevičienė, A., Šiaurytė, K., Kuiper, E., & Grabrucker, A. M. (2023) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2023.104763 · Cited by 19
“3 deletions (Tabet et al., 2017; Denayer et al., 2012; Samogy-Costa et al., 2019; Lindquist et al., 2005), and 17% of PMS individuals with SHANK3 variants (De Rubeis et al.”
BackgroundDeletion of the last exon of SHANK3 gene produces the full Phelan–McDermid phenotype: A case report
Macedoni-Lukšič, M., Krgović, D., Zagradišnik, B., & Kokalj-Vokač, N. (2013) · Gene · doi:10.1016/j.gene.2013.03.141 · Cited by 19
“Denayer et al. (2012) reported a progressive loss of gross and fine motor skills in seven patients.”
BackgroundLu, Z. A., Mu, W., Osborne, L. M., & Cordner, Z. A. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-225119 · Cited by 17
Philippe, A., Craus, Y., Rio, M., Bahi‐Buisson, N., Boddaert, N., Malan, V., Bonnefont, J., & Robel, L. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0631-6 · Cited by 19
“[17] reported a deletion of SHANK3 encompassing the first 19 exons associated with bipolar disorder with progressive loss of skills in one of their 7 patients (patient 1); Bonaglia et al.”
BackgroundPhelan, K., Boccuto, L., & Sarasua, S. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800109-7.00021-2 · Cited by 17
Evaluating the association between the SHANK3 gene and bipolar disorder
Zhang, C., Wu, Z., Hong, W., Peng, D., & Fang, Y. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.07.058 · Cited by 16
Asta, L., Ricciardello, A., Cucinotta, F., Turriziani, L., Boncoddo, M., Bellomo, F., Angelini, J. M., Gnazzo, M., Scandolo, G., Pisanò, G., et al. (2024) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-024-09572-7 · Cited by 15
Barbier, M., Rajamani, K. T., Netser, S., Wagner, S., & Harony‐Nicolas, H. (2025) · Advanced Science · doi:10.1002/advs.202414813 · Cited by 15
Droogmans, G., Vergaelen, E., Buggenhout, G. V., & Swillen, A. (2021) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/jar.12858 · Cited by 15
Self-citationLandry, O., François, A., Mi-mba, M.-F. O. M., Traversy, M.-T., Tremblay, C., Émond, V., Bennett, D. A., Gylys, K. H., Buxbaum, J. D., & Calon, F. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1945-22.2023 · Cited by 14
“Consistent with a possible role in neurodegeneration and not just in neurologic development, SHANK3 defect is suspected to cause symptom aggravation and skill regression in young patients and possibly dementia-like symptoms in older subjects (Denayer et al., 2012; Vucurovic et al., 2012; Guilmatre et al., 2014).”
BackgroundInfluentialJungová, P., Čumová, A., Kramarová, V., Lisyová, J., Ďurina, P., Chandoga, J., & Böhmer, D. (2018) · Neurocase · doi:10.1080/13554794.2018.1542007 · Cited by 14
“…occurs most dramatically after acute events such as a septic shock, epileptic state, catatonic phase, malignant neuroleptic syndrome and side effects of medications with various degrees of recovery in social/motoric abilities (Denayer et al., 2012; Egger et al., 2016; Serret et al., 2015).”
BackgroundInfluentialPsychiatric assessment in Phelan-McDermid Syndrome (22q13 deletion syndrome)
Kildahl, A. N., Berg, L. K., Nilssen, A. L. E., Bjørgo, K., Rødningen, O. K., & Helverschou, S. B. (2018) · Journal of Intellectual & Developmental Disability · doi:10.3109/13668250.2018.1440135 · Cited by 11
“It has been speculated whether it is connected to the deletion (Anderlid et al., 2002), or if it may be secondary to psychiatric disorder (Denayer et al., 2012; Serret et al., 2015; Vucurovic et al., 2012).”
BackgroundInfluentialWeng, X., Zhou, D., Liu, F., Zhang, H., Ye, J., Zhang, Z., Zhang, D., Wang, Y., Tao, L., Cao, L., et al. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-31 · Cited by 11
“Plcb1 is of critical importance in codifying neurotransmitter receptors and is associated with schizophrenia [46,47].”
BackgroundDhossche, D. M., de Billy, C. D. C., Laurent‐Levinson, C., Normand, M. L., Recasens, C., Robel, L., & Philippe, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1186555 · Cited by 9
Sensory processing and adaptive behavior in Phelan-McDermid syndrome: a cross-sectional study
Serrada-Tejeda, S., Cuadrado, M. L., Martínez-Piédrola, R. M., Máximo-Bocanegra, N., Sánchez-Herrera-Baeza, P., Camacho-Montaño, L. R., & Pérez‐de‐Heredia‐Torres, M. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04564-y · Cited by 9
Descriptive Analysis of Adaptive Behavior in Phelan–McDermid Syndrome and Autism Spectrum Disorder
Serrada-Tejeda, S., Martínez-Piédrola, R. M., Máximo-Bocanegra, N., Sánchez-Herrera-Baeza, P., & Pérez‐de‐Heredia‐Torres, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.893003 · Cited by 8
“The results obtained in this study show as in previous studies (Havens et al., 2004; Dhar et al., 2010; Phelan et al., 2011; Shaw et al., 2011; Denayer et al., 2012; Phelan and McDermid, 2012; Zwanenburg et al., 2016; Brignell et al., 2021), that people with PMS present a low level of adaptive…”
BackgroundResultSarasua, S. M., DeLuca, J. M., Rogers, C. R., Phelan, K., Rennert, L., Powder, K. E., Weisensee, K. E., & Boccuto, L. (2023) · Genes · doi:10.3390/genes14030540 · Cited by 8
Sungur, A. Ö., Redecker, T. M., Andres, E., Dürichen, W., Schwarting, R. K. W., del Rey, A., & Wöhr, M. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00419 · Cited by 8
“Our observation that Frontiers in Molecular Neuroscience | www.frontiersin.org 1 November 2018 | Volume 11 | Article 419 psychostimulant-induced hyperactivity is reduced rather than enhanced in Shank1−/− mice clearly speaks against a behavioral phenotype with relevance to BPD. Lack of BPD-like phenotype is consistent…”
BackgroundInfluentialBoley, G., Pierri, J. N., Finegold, D. N., & Pan, L. A. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-256155 · Cited by 7
Qiao, S.-N., Wang, S. E., Kim, K.-Y., Jo, S., & Jiang, Y.-H. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03534-2 · Cited by 5
Phelan-McDermid syndrome-associated psychosis: a systematic review
Colijn, M. A. (2024) · Acta Neuropsychiatrica · doi:10.1017/neu.2024.46 · Cited by 5
Retrospective Reports of Skill Attainment and Loss in Phelan-McDermid Syndrome
Farmer, C., Giserman‐Kiss, I., Mohanty, E., Soorya, L. V., Şahin, M., Kolevzon, A., Buxbaum, J. D., Berry‐Kravis, E., Powell, C. M., Bernstein, J. A., et al. (2025) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-130.5.362 · Cited by 4
“In some cases, losses occur subsequent to seizures or other medical problems (Denayer et al., 2012; Kolevzon et al., 2014), but not always (Reierson et al., 2017).”
SHANK Mutations May Disorder Brain Development
Poot, M. (2014) · Molecular Syndromology · doi:10.1159/000368949 · Cited by 4
“Conversely, duplication of SHANK3 induces bipolar disorders with progressive loss of skills, attention deficit hyperactivity disorder (ADHD), or episodes of status epilepticus [Denayer et al., 2012; Han et al., 2013].”
BackgroundPhelan, K., Rogers, R. C., & Boccuto, L. (2020) · Wiley eBooks · doi:10.1002/9781119432692.ch22 · Cited by 4
Hickey, P. C., Patel, H., & Neumeyer, A. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-76269-7_13 · Cited by 4
Zwanenburg, R. J., Dijkhuizen, T., de Groot, M. J., Nampoothiri, S., Willemsen, M. H., Dulfer, E., Thampi, M. V., de Leeuw, N., & van Ravenswaaij‐Arts, C. M. A. (2018) · OBM Genetics · doi:10.21926/obm.genet.1804050 · Cited by 3
Skavås, M. R., Rognlid, M., & Kildahl, A. N. (2024) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2024.2345958 · Cited by 3
“…of bipolar disorder in PHMDS indicate that treatment strategies are generally in line with the guidelines for the treat-ment of bipolar disorder in the general population (Denayer et al. 2012; Egger et al. 2016; Kolevzon et al. 2019; Srivastava et al. 2023; Verhoeven, Egger, and de Leeuw 2020).”
Opportunities for ABA intervention in Phelan–McDermid syndrome
Schroeder, K. A., Witts, B. N., & Traub, M. R. (2021) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2021.1895698 · Cited by 3
“and Benzodiazepines Denayer et al. (2012) Case report Possible overdose and skill regression (Continued) 986 International Journal of Developmental Disabilities 2022 VOL. 68 NO. 6 daily living (Pierce and Schreibman 1994), communication (Ghaemmaghami et al. 2018), social (Stauch et al. 2018), play (Najdowski et al. 20…”
BackgroundGenetic Disorders and Dual Diagnosis: Building Clinical Management on Etiology and Neurocognition
Bos‐Roubos, A. G., van Dongen, L. C. M., Verhoeven, W. M. A., & Egger, J. I. M. (2020) · Autism and child psychopathology series · doi:10.1007/978-3-030-46835-4_4 · Cited by 3
Varella-Branco, E., Shephard, E., Toledo, V. H. C., Ramos, I. C., Lacerda, E. C. M., Carvalho, L. L. M., Fiuza, M. A., Paschalidis, M., Costa, C. I. S., Girardi, A. C. S., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03433-y · Cited by 2
Pagano, J., Perez Arevalo, A., Nosanova, A., Bauer, H. F., Loth, E., Andres, S., Becker, F., Otto, M., Stefanoni, A., Verpelli, C., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03932-8 · Cited by 2
“The core clinical features of PMS include neonatal hypotonia, dysmorphic features, global developmental delay, absent or severely impaired speech, intellectual disability, seizures, and ASD associated behavioural phenotypes [1 – 3].”
Organism Models: Choosing the Right Model
Lévy, N., & Roubertoux, P. L. (2014) · Neuromethods · doi:10.1007/978-1-4939-2250-5_1 · Cited by 2
Analyses phénotypiques in vitro et in vivo de mutations de novo tronquantes dans le gène SHANK3
Vitrac, A. (2020) · theses.fr (ABES) · doi:10.70675/49ade836zc9baz4a38zb08fz51b291137c65 · Cited by 2
Sun, Y., Xia, Y., Zhi, Q., Guo, P., Cui, W., & Liu, X. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i2.101948 · Cited by 1
Li, L., Zhang, J., Shi, X., Huang, Y., Chang, X., & Zhang, L. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1699311 · Cited by 1
“Individuals with PMS have an increased risk of experiencing bipolar disorder, with an associated risk of cognitive and behavioral regression (Breckpot et al., 2016; Denayer et al., 2012; Egger et al., 2016; Serret et al., 2015).”
Sandoni, L., Chehbani, F., Asta, L., Camia, M., Ricciardello, A., Tomaiuolo, P., Cucinotta, F., Turriziani, L., Boncoddo, M., Bellomo, F., et al. (2026) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-026-09708-x · Cited by 1
First-Tier Array CGH in Clinically Variable Entity Diagnosis: 22q13.3 Deletion Syndrome
Budișteanu, M., Ţuţulan-Cuniţă, A. C., Focșa, I. O., Papuc, S. M., & Arghir, A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89399 · Cited by 1
Autism Spectrum Disorders Versus Genetic Syndromes
Capal, J. K., & Jeste, S. (2022) · Oxford University Press eBooks · doi:10.1093/med-psych/9780197516881.003.0010 · Cited by 1
Phelan–McDermid Syndrome: Expanding the Phenotype
El-Bassyouni, H. T., Eid, O. M., Ismail, S. I., El‐Ruby, M., Ashaat, E. A., Mahrous, R., Hussein, S. H., Kamel, A. I., Zaki, M. S., Hamed, K., et al. (2022) · Middle East Journal of Medical Genetics · doi:10.21608/mxe.2023.287525 · Cited by 1
Phelan-Mcdermid syndrome: three case reports and a literature review
Berrada, S., Amal, T., Maarouf, F., Gazzaz, B., & Dehbi, H. (2024) · European Journal of Medical Case Reports · doi:10.24911/ejmcr.173-1685450588 · Cited by 1
“However, the terminal deletion could be inherited from an affected parent, which is very rare, and only one case has been described in the literature [10].”
BackgroundMartins, M. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Loss of ASD-associated scaffold Shank3 induces dendritic accumulation of pTau
Steffke, C. (2024) · doi:10.18725/oparu-52388 · Cited by 1
Using Shank3 Model Mice to Probe the Neuroanatomic Basis of Autism
Bey, A. L. (2017) · DukeSpace (Duke University)
Ferhat, A.-T. L. S. (2018) · theses.fr (ABES) · doi:10.70675/55407f0fz70a6z40f9z915bz6cc3e54a33dd
Martsenkovsky, I., Martsenkovska, I. I., Makarenko, H. V., Skrypnyk, T., & Zdoryk, I. F. (2021) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.17.2.2021.229894
Metadata
- Authors
- Denayer, A., Van Esch, H., de Ravel, T., Frijns, J.-P., Van Buggenhout, G., Vogels, A., Devriendt, K., Geutjens, J., Thiry, P., & Swillen, A.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Venue
- Molecular Syndromology
- Publisher
- S. Karger AG
- Published
- 2012
- Volume
- 3
- Issue
- 1
- Pages
- 14-20
- ISSN
- 1661-8769 (ISSN-L)
- 1661-8777
- PMC
- PMC3398818
- OpenAlex
- W2072159751
- Cited by
- 99
- References
- 16
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 12 · 2022: 6 · 2021: 10 · 2020: 8 · 2019: 4 · 2018: 11 · 2017: 4 · 2016: 7 · 2015: 9 · 2014: 9 · 2013: 5
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Molecular Syndromology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Abstract book
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Life Sciences › Neuroscience › Developmental Neuroscience › Williams Syndrome Research
- Keywords
- 22q13 deletion syndrome, SHANK3, bipolar disorder, attention deficit hyperactivity disorder, intellectual disability, mental illness, developmental decline, autism-like behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.